Pfizer Inc. (NYSE:PFE) Stake Decreased by Marble Harbor Investment Counsel LLC

Marble Harbor Investment Counsel LLC lowered its position in Pfizer Inc. (NYSE:PFE) by 0.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 333,088 shares of the biopharmaceutical company’s stock after selling 325 shares during the quarter. Pfizer makes up about 2.9% of Marble Harbor Investment Counsel LLC’s investment portfolio, making the stock its 10th largest holding. Marble Harbor Investment Counsel LLC’s holdings in Pfizer were worth $14,539,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in PFE. Home Federal Bank of Tennessee increased its holdings in Pfizer by 0.8% in the 4th quarter. Home Federal Bank of Tennessee now owns 29,695 shares of the biopharmaceutical company’s stock valued at $1,297,000 after buying an additional 249 shares during the period. Congress Asset Management Co. MA increased its holdings in Pfizer by 2.0% in the 4th quarter. Congress Asset Management Co. MA now owns 13,235 shares of the biopharmaceutical company’s stock valued at $578,000 after buying an additional 254 shares during the period. D.B. Root & Company LLC increased its holdings in Pfizer by 0.7% in the 4th quarter. D.B. Root & Company LLC now owns 36,078 shares of the biopharmaceutical company’s stock valued at $1,575,000 after buying an additional 255 shares during the period. Cottage Street Advisors LLC increased its holdings in Pfizer by 4.0% in the 4th quarter. Cottage Street Advisors LLC now owns 6,677 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 255 shares during the period. Finally, Advocacy Wealth Management Services LLC increased its holdings in Pfizer by 48.2% in the 4th quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 258 shares during the period. Hedge funds and other institutional investors own 71.83% of the company’s stock.

NYSE:PFE traded down $0.11 during mid-day trading on Friday, hitting $43.32. 37,058,693 shares of the company’s stock were exchanged, compared to its average volume of 23,986,496. The stock’s 50 day moving average is $42.32. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.54 and a quick ratio of 1.27. Pfizer Inc. has a fifty-two week low of $36.00 and a fifty-two week high of $46.47. The company has a market cap of $239.02 billion, a price-to-earnings ratio of 14.44, a P/E/G ratio of 2.49 and a beta of 0.65.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.75 by $0.10. Pfizer had a net margin of 21.31% and a return on equity of 27.48%. The business had revenue of $13.12 billion for the quarter, compared to the consensus estimate of $13.01 billion. During the same period last year, the company earned $0.77 EPS. The firm’s revenue was up 1.6% compared to the same quarter last year. On average, analysts forecast that Pfizer Inc. will post 2.88 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, August 2nd will be given a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a yield of 3.32%. Pfizer’s dividend payout ratio is presently 48.00%.

In other news, major shareholder Pfizer Inc purchased 50,000 shares of the stock in a transaction on Monday, May 13th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $850,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the transaction, the insider now owns 80,094 shares of the company’s stock, valued at approximately $3,524,136. The disclosure for this sale can be found here. 0.09% of the stock is owned by company insiders.

Several equities analysts have commented on the stock. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, April 10th. Credit Suisse Group restated a “buy” rating and issued a $48.00 price target on shares of Pfizer in a research note on Monday, June 17th. Goldman Sachs Group restated a “buy” rating and issued a $49.00 price target on shares of Pfizer in a research note on Monday, June 17th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $46.00 price target on shares of Pfizer in a research note on Friday, April 19th. Finally, Bank of America raised their price target on shares of Pfizer from $45.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Thirteen investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $46.22.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: Why is Cost of Capital Important?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.